PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Talking Medicines set for further growth with three senior appointments

Talking Medicines, the world’s first social intelligence company for the pharmaceutical industry, is gearing up for growth in 2021 with three senior appointments.

Tatiana Nantes joins the team as Head of Product from VMware, bringing 10 years of international agile product management experience to the award-winning scale-up. In the newly created role, Tatiana will be responsible for the delivery of social intelligence solutions for the pharmaceutical industry.

Also joining the team is Tom Lynch as Senior Engineer and Adrian Mursec as Frontend Developer.

Tom is a software engineer based in London with a background in consultancy and broad experience in data science, analytics and data engineering, having built and maintained big data pipelines in the cloud for clients in retail, energy and insurance sectors.

Adrian is a Frontend developer based in Manchester with 15 years’ experience of has working with startups, agencies and large tech companies.

The latest hires follow a £1.1 million funding deal led by Tern PLC, secured in November 2020, to scale up Talking Medicine’s AI-based data technology platform to track patient experience for the pharmaceutical industry. Following the investment by Tern, Al Sisto joined the board of Talking Medicines as Chairman.

As well as taking on new staff this year, Talking Medicines is using the funds to support the launch and roll-out of a new AI data platform, which provides social intelligence insights for the world’s leading drug brands, delivering more effective marketing and better health outcomes for patients

Talking Medicines CEO, Jo Halliday, said: “2021 is a huge year for Talking Medicines. Having been in a deep R&D stage developing our AI offering, we are now in a great position to launch our platform to the pharma industry and realise our ambition of supporting pharma to deliver more effective drug marketing and, ultimately, better health outcomes for patients. Tatiana, Tom and Adrian will all provide invaluable expertise and experience as we embark on this next phase of growth with a view to securing Series A funding later this year.”

Tatiana Nantes said, “Having been introduced to the world of tech shortly after leaving University, ever since I have been part of building products that are used by millions of people around the world in companies such as Time Out, Momondo and VMware.

I’m really excited to be joining the team at Talking Medicines at such an important stage in its development. The opportunity to play a crucial role in helping to launch and develop a world-class data solution while also delivering a significant social impact was too good to miss.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026